---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040584"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:39:52.048119+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myomo Q2 revenue up 62% to $6.0M; net loss narrows to $1.0M

## Summary
- Product revenue $4.2M (+15% YoY); revenue units 97 (+21%). Total revenue includes $1.7M JV license fee.
- Gross margin 71.8% vs 65.3%; net loss $1.0M ($0.04/sh) vs $2.9M loss ($0.42/sh) YoY.
- Patient pipeline 969 candidates (+27%); 408 new candidates added in Q2 (+57%).
- CMS proposed rule may expand brace definition to include MyoPro; Medicare Part B reimbursement anticipated in 6-12 months.
- Outlook: modest Q3 YoY growth; full-year product revenue growth target of 20-30% dependent on authorizations.

## SEC filing metadata
- accession: 0000950170-23-040584
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/0000950170-23-040584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/myo-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040584
- JSON: https://secwatch.observer/filing/0000950170-23-040584.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040584.txt

## Key facts
- Earnings Releases
  MYOMO, INC. reported the second quarter ended June 30, 2023 results: revenue $6.0 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $6.0 million
  - Result: reported results
  source text: EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/0000950170-23-040584-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.